Total Joints: Bundled Payments Driving Procedural Innovation
Manufacturers bracing for CMS' new mandatory bundled payment program for total hip and knee replacement surgery may be able to breathe a sigh of relief as hospitals are expected to target post-acute-care rather than implants to bring down costs. Amid these changes, orthopedic manufacturers are helping hospitals address bundled payments by developing innovative solutions that improve procedural efficiencies, recovery times, costs and patient outcomes, including outpatient total joint surgery, robotics, custom implants, and patient-specific instrumentation.
Keep up with the top medtech business and regulatory news.
More from United States
- • By
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
- • By
US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.
- • By
With the reversal of the Chevron doctrine in June, lower courts will now have more say in deciding regulatory statutes when the language is murky. But will that open the door to more legal challenges from the healthcare industry against government regulations it finds unfavorable? A pair of legal experts recently discussed the potential implications of the Court’s decision.
- • By
The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.
More from North America
- • By
This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.
- • By
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.
- • By
The Food and Drug Administration’s final guidance outlines the agency’s thinking for sponsors submitting de novo requests electronically, which they must starting in October 2025.
